Brief: Sunesis Says Company, Denovo Entered License Agreement For Vosaroxin

Viracta Therapeutics

06/12/2019 21:58

Dec 6 (Reuters) - Sunesis Pharmaceuticals Inc  SNSS.O :
    * SUNESIS PHARMACEUTICALS -  ELIGIBLE TO RECEIVE AN UPFRONT
PAYMENT, UP TO $57.0 MILLION FROM LICENSE AGREEMENT DENOVO
BIOPHARMA FOR VOSAROXIN

Source: (https://bit.ly/38dgjSv)
Further company coverage:  SNSS.O 

 ((Reuters.Briefs@thomsonreuters.com;))